ObjectiveTo evaluate the efficacy and safety of neoadjuvant PD-1 inhibitor combined with chemotherapy (nab-paclitaxel + cisplatin) in patients with locally advanced hypopharyngeal squamous cell carcinoma.MethodsA retrospective analysis was conducted on 75 patients with locally advanced (stage III-IVA) hypopharyngeal cancer diagnosed at the First Affiliated Hospital of Xiamen University between January 2021 and May 2023. All patients received at least 2 cycles of neoadjuvant immunochemotherapy followed by radical surgery and adjuvant radiotherapy. Objective response rate (ORR), major pathological response (MPR), pathological complete response (pCR), larynx-preserving surgery rate, progression-free survival (PFS), and safety were evaluated.ResultsAmong 75 patients, the ORR was 77.3% (58/75), MPR rate was 78.7% (59/75), standard pCR rate (primary + lymph nodes) was 17.3% (13/75), primary tumor pCR rate was 26.7% (20/75), and larynx-preserving surgery rate was 86.7% (65/75). With a median follow-up of 26 months, the 12-month and 24-month overall survival rates were 93.3% and 76.0%, respectively, and the PFS rates were 92.0% and 76.0%, respectively. The MPR group demonstrated significantly superior PFS compared to the non-MPR group (HR = 0.052, 95% CI: 0.019-0.140, P < 0.001), with 24-month PFS rates of 89.7% and 12.5%, respectively. The ORR group also showed significantly superior PFS compared to the non-ORR group (HR = 0.29, 95% CI: 0.13-0.66, P = 0.003), with 24-month PFS rates of 86.2% and 41.2%, respectively. Concordance between radiological and pathological assessments was moderate (κ=0.417, P < 0.001). The safety profile was favorable, with no grade 3–5 treatment-related adverse events observed.ConclusionNeoadjuvant PD-1 inhibitor combined with chemotherapy induces significant radiological and pathological responses in patients with locally advanced hypopharyngeal cancer, effectively improving larynx-preserving surgery rate and progression-free survival with a favorable safety profile. Pathological assessment (particularly MPR) may provide complementary prognostic information to radiological assessment.This regimen demonstrates promising short-term efficacy and larynx preservation benefits, warranting further prospective validation.

Objective:This study aimed to investigate the effect of preoperative neoadjuvant immunochemotherapy (NAICT) on the prognosis of patients with locally advanced oral squamous cell carcinomas (OSCC), thereby providing evidence-based guidance for the clinical management of OSCC. Methods:We conducted a retrospective cohort study of OSCC cases treated at our institution between 2017 and 2022. Kaplan-Meier survival curves, along with univariate and multivariate Cox regression analyses, were employed to identify independent factors influencing 3-year overall survival (OS) and disease-free survival (DFS) rates. Results:A total of 158 patients with locally advanced OSCC were included. 119 patients received simple surgical treatment, 15 patients underwent neoadjuvant chemotherapy (NAC) followed by surgery and 24 patients underwent NAICT followed by surgery. Multivariate analysis identified differentiation (P = 0.041), negative margins (P = 0.043), N stage (P = 0.046), treatment strategy (P = 0.016), postoperative recurrence (P < 0.001), and postoperative metastasis (P = 0.044) as independent factors influencing 3-year OS. For 3-year DFS, the independent factors included negative margins (P = 0.017), N stage (P = 0.006), treatment strategy (P = 0.004), postoperative recurrence (P < 0.001), and post-operative metastasis (P < 0.001). Compared to direct surgery, surgery following NAC showed no significant difference in 3-year OS (53.3% vs. 57.1%, P = 0.701) and 3-year DFS (33.3% vs. 52.9%, P = 0.099). Compared to direct surgery, preoperative NAICT significantly improved 3-year OS (82.4% vs. 57.1%, P = 0.004) and 3-year DFS (83.3% vs. 52.9%, P = 0.007). Furthermore, compared to surgery following NAC, preoperative NAICT was associated with a significantly improved 3-year OS (82.4% vs. 53.3%, P = 0.03) and 3-year DFS (83.3% vs. 33.3%, P = 0.001). Treatment-related adverse events occurred in 70.8% of patients receiving NAICT. All events were grade 1-2 in severity and resolved following treatment. Conclusion:Compared to direct surgery or NAC followed by surgery, preoperative NAICT demonstrated a more favorable impact on the prognosis of patients with locally advanced OSCC, while exhibiting manageable treatment-related adverse effects.

BACKGROUND:Conventional treatment strategies and immunotherapy yield low response rates in head and neck squamous cell carcinoma (HNSCC). This study aimed to explore the potential of immunosuppressive receptor leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) for developing effective immunotherapies for HNSCC. METHODS:Clinical data collection and analysis were determined using Tumor Immunity Estimation Resource Database (TIMER) and Cancer Treatment Response gene signature DataBase (CTR-DB). Immunohistochemistry was used to detect protein level in fresh breast cancer tissues. RNA sequencing was employed to screen the downstream signaling pathway in WBP2-overexpressed cells. Tumor xenograft model and Flow Cytometry were performed to monitor tumor growth and cell apoptosis, respectively. RESULTS:In this study, high expression of LILRB1 in HNSCC tissues was observed compared to normal tissues. HNSCC patients with high LILRB1 expression exhibited a better prognosis, which was influenced by tumor mutation burden. Functional network analysis revealed a positive association between LILRB1 and chemokine signaling pathways. Copy number variation of LILRB1 was positively correlated with the infiltration of CD8+ T cells and M1 macrophages. The prognostic effect of LILRB1 depends on CD8+ T-cell abundance, especially in HNSCC with a low neoantigen load. High LILRB1 expression was associated with a higher immune score, indicating favorable outcomes in HNSCC patients receiving immunotherapy. Notably, LILRB1 was specifically expressed in SPP1-ACP5+ macrophages; in these cells, high LILRB1 might reduce the proportion of cancer cells via the SPP1-CD44 axis, and subsequently regulate CD8+ T cell enrichment through the C-X-C motif chemokine 13 (CXCL13)-CXCR5 axis. CONCLUSION:Collectively, high LILRB1 expression in HNSCC was accompanied by the infiltration of various immune effector cells. LILRB1 may shape the tumor microenvironment of HNSCC, mediating the interactions between cancer cells and macrophages, as well as between cancer cells and CD8+ T cells, via the SPP1-CD44 and CXCL13-CXCR5 axes. Our findings illustrate that LILRB1 serves as a prognostic-related biomarker associated with immune infiltration in HNSCC.

The etiology and mechanism causing Age-related hearing loss (ARHL) are not understood. This study aimed to investigate the molecular mechanism of interleukin 8 (IL-8) associated with ARHL. Sera content of IL-8 was significantly higher in patients with ARHL than normal volunteers and had a positive association with disease severity of ARHL. Human IL-8 (hIL-8) could exacerbate the progressive ARHL with time increase and promoted apoptosis of hair cells in cochlea. As the important component in maintaining the integrity of the blood-labyrinth barrier (BLB) and hearing function, cell viability of perivascular-resident macrophage-like melanocytes (PVM/Ms) was restrained while apoptosis of PVM/Ms was enhanced in the presence of hIL-8. Using a cell culture-based in vitro model, the permeability of the endothelial cells (ECs) monolayer increased markedly in the presence of IL-8-treated PVM/Ms or PVM/Ms-derived from LV5-hIL-8 mice as compared with the presence of PVM/Ms-derived from wild type (WT) mice or 12-months WT mice. Mechanistically, IL-8 exposure enhanced the expression of histone deacetylase 3 (HDAC3) in PVM/Ms and HDAC3 inhibitor significantly blocked the permeability of the ECs in the presence of IL-8-treated PVM/Ms. Besides, HDAC3 inhibitor had a protective effect on hIL-8-launched ARHL in mice. Collectively, the elevated of serum IL-8 in ARHL patients activated the activity of HDAC3 in PVM/Ms, subsequently increased the permeability of the ECs, resulting in the impairments of the BLB and hair cells in cochlea. Possibly, IL-8 could be used in the diagnosis of ARHL and these findings might help to identify the clinical therapeutic direction for ARHL.

To explore the therapeutic potential of blocking thymic stromal lymphopoietin (TSLP) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), we conducted a phase 1b/2a, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of CM326, a monoclonal antibody against TSLP. We enrolled 84 eligible patients with uncontrolled CRSwNP and stratified them based on baseline tissue eosinophil count. Patients are assigned to receive CM326 220 mg (n = 40) or placebo (n = 20) every 2 weeks (Q2W) and CM326 220 mg (n = 20) or placebo (n = 4) every 4 weeks (Q4W) for 16 weeks. Subsequently, all patients continue on CM326 220 mg Q2W or Q4W for an additional 36 weeks, followed by a 12-week follow up. Primary endpoints are safety of CM326 and change from baseline in NPS at week 16 in patients with eosinophilic CRSwNP (ECRSwNP). Main secondary endpoints include the change from baseline in NPS at week 16 in non-eosinophilic CRSwNP (nonECRwNP) and pharmacodynamic markers. Throughout the 64-week study, all treatment-emergent adverse events (TEAEs) are mild or moderate. CM326 Q2W improves NPS in patients with ECRSwNP compared with placebo at week 16 (mean difference [95% CI], -1.2 [-2.3 to -0.1], P = 0.04), with sustained benefits during the open-label and follow-up periods. Notably, peripheral blood and tissue eosinophil counts and concentrations of plasma IL-13 and IL-5 are reduced by week 16 with the treatment of CM326 Q2W versus placebo. A post-hoc analysis demonstrates that all participants with baseline TSLP > 330 fg/mL achieve a substantial reduction in NPS by week 16 with the treatment of CM326 Q2W (mean difference vs. placebo: -1.75 [95%CI, -3.06 to -0.44], P = 0.01). Overall, CM326 is well tolerated and effective in patients with uncontrolled ECRSwNP. A baseline plasma TSLP level of 330 fg/mL may serve as a predictive marker for treatment efficacy of CM326. ClinicalTrials.gov Identifier: NCT05324137.

Nasopharyngeal carcinoma (NPC) has hidden onset, low rate of early diagnosis, and most of them have metastases at the time of diagnosis. The specific pathogenesis of NPC is still unclear. Polycyclic aromatic hydrocarbons (PAHs) are a large group of contaminants produced by the incomplete combustion of organic matter and widespread in the air. Many of these compounds are mutagenic and carcinogenic. PAHs plays an important role in mutagenic and carcinogenic, while its role in NPC still needs further elucidation. In this study, CNE-2 cells were stimulated by PAHs, then the expression of aryl hydrocarbon receptor (AhR) and CYP1A2 were respectively examined using Real-Time fluorescence quantitative PCR (qRT-PCR) and Western Blot. CNE-2 cells proliferation, migration, invasion and apoptosis were examined by CCK-8, Wound-Healing Assay, Transwell, Flow Cytometry, respectively. We found that AhR expression was increased while the level of apoptosis was inhibited by PAHs. While the ability of cell invasion was weakened, proliferation and migration were not significantly different. After treated by PAHs and ITE, the effect of PAHs on promoting AhR expression was significantly inhibited and apoptosis was up-regulated. The present study found that, PAHs inhibit apoptosis of NPC cells and promote the expression of AhR. Besides, PAHs participates in NPC occurrence and development by regulating AhR expression. Collectively, these findings may provide a possible strategy for the clinical treatment of NPC.

Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.

Objective:This study was aimed to evaluate the clinical effectiveness of tympanoplasty using auricular cartilage combined with balloon eustachian tuboplasty for the treatment of adhesive otitis media（adhesive otitis media, AdOM） under endoscopic. Methods:A retrospective analysis was conducted on 60 patients with unilateral adhesive otitis media who visited Department of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital of Xiamen University between January 2017 and February 2022. All patients were divided into three groups: ①conservative treatment group;②simple tympanoplasty group; ③tympanoplasty combined with balloon dilation group（BET group）. All patients were regularly assessed for the improvement of tympanic membrane morphology, hearing, and Eustachian tube function, as well as complications, after treatment. Results:There was no significant improvement in eardrum morphology, hearing, or eustachian tube function in the conservative treatment group（P>0.05）; both the simple tympanoplasty group and the BET group showed significant improvements in eardrum morphology and hearing after surgery（P<0.01）; In terms of Eustachian tube function improvement, the BET group showed significantly greater improvements in Eustachian tube manometry（TMM） and Eustachian Tube Dysfunction Questionnaire（ETDQ-7） scores compared to the tympanoplasty alone group（P<0.01）. Conclusion:Tympanoplasty using auricular cartilage combined with balloon eustachian tuboplasty shows good clinical outcomes in the treatment of adhesive otitis media, significantly ameliorating patients' subjective symptoms such as tinnitus and ear congestion after surgery, thereby improving the patient's quality of life.

Objective This study is aimed to evaluate the efficacy and safety of PD-1 inhibitors combined with neoadjuvant chemotherapy in patients with locally advanced hypopharyngeal and oropharyngeal cancer prior to surgical resection.Methods This retrospective analysis included 42 patients diagnosed with locally advanced hypopharyngeal and oropharyngeal cancer. The efficacy, safety, survival, and laryngeal preservation rate were evaluated.Results A total of 42 patients were included in this retrospective analysis, of whom 28 had hypopharyngeal cancer and 14 had oropharyngeal cancer. Of the 42 patients, 14 (33.3%) achieved a pathological complete response (PCR) at the primary site, 20 (47.6%) achieved a major pathological response (MPR), and 8 (19%) had an incomplete pathological response (IPR) at the primary lesion. A PCR at both the primary site and the neck lymph nodes was observed in 9 patients (21.4%). The laryngeal preservation rate was 92.9% (26/28) in patients with hypopharyngeal cancer. The median follow-up time was 10.5 months. The median progression-free survival (PFS) was 26.42 months (95% CI, 23.416-29.424), and the median overall survival (OS) was 27.1 months (95% CI, 24.316-29.884). The 1-year PFS rate was 83.1%, and the 1-year OS rate was 85.9%.Conclusion Combination therapy with PD-1 inhibitors and neoadjuvant chemotherapy has demonstrated superior efficacy and safety as a preoperative treatment for locally advanced hypopharyngeal and oropharyngeal cancer. Notably, this treatment regimen does not increase the risk of severe postoperative complications and has shown promising results in improving laryngeal preservation rates.

ObjectiveThe objective of this study is to assess the prognostic value of Ki67 and p16 proteins in laryngeal cancer.Materials and methodsThis retrospective cohort analysis comprised 260 patients diagnosed with laryngeal cancer. Immunohistochemistry (IHC) was employed to assess the expression levels of p16 and Ki67, and their correlation with the survival time of laryngeal cancer patients was analyzed.ResultsThe Ki67 index level exhibited a significant association with the prognosis of laryngeal cancer. Patients with higher Ki67 index levels demonstrated shorter survival times, more severe pathological classification, and higher tumor stages (P < 0.05). Conversely, no significant differences in prognostic characteristics of laryngeal cancer were observed in the p16 (-/+) population (P > 0.05). The median survival times for patients with Ki67 index levels of 0-35%, 36-70%, and 70-100% were 3.54 years, 2.10 years, and 1.92 years, respectively. After adjusting for age, smoking, alcohol consumption, pathological classification, surgical intervention, recurrence, and metastasis, the risk of death for patients with Ki67 index levels of 70-100% was 2.0504 times higher than that of patients with Ki67 index levels of 0-35% (95% CI: 1.2997-3.2345, P = 0.0020).ConclusionThe Ki67 index level is strongly associated with survival time and the risk of death in laryngeal cancer, making it a valuable prognostic indicator. However, the prognostic value of p16 levels in laryngeal cancer is limited. These findings provide important insights for prognosis evaluation and treatment decision-making in patients with laryngeal cancer.

Our study had demonstrated that WW domain-binding protein 2 (WBP2) conferred chemoresistance in breast cancer (BC). However, the underlying mechanism remains unclear. Herein, a decreased expression of itchy E3 ubiquitin protein ligase (ITCH) was observed in drug-resistant BC tissues which negatively regulated the expression of WBP2. However, ligase-deficient ITCH C830A mutant missed this function. WBP2 upregulation-initiated the chemoresistance to doxorubicin was reversed by exogenous ITCH, which was not affected by ITCH C830A mutant. In in vivo model, exogenous ITCH obstructed WBP2-mediated chemoresistance, which was destroyed by the proteasome inhibitor (MG132). Upon RNA sequencing, the excessive activations of angiomotin-like 2 (AMOTL2) and c-JUN (Jun proto-oncogene, AP-1 transcription factor subunit) were screened in WBP2-overexpressed BC cells. Additionally, AMOTL2 and endonuclear phosphorylated c-JUN were at a high level in chemoresistant BC tumors and WBP2-overexpressed BC cells. Mechanistically, exogenous ITCH transfection prevented the activation of AMOTL2/c-JUN induced by WBP2 overexpression, which was restored by MG132-mediated inhibition on ITCH activation. The increase of multiple drug-resistant proteins caused by WBP2 upregulation were restrained by AMOTL2 knockdown or c-JUN antagonist, respectively. Our findings present how ITCH/WBP2 signaling functions to link the intricate AMOTL2/c-JUN signaling networks in chemoresistant BC cells. Targeting WBP2 combined with c-JUN inhibitors may be a potential option to overcome chemoresistance in breast cancer patients

PurposeTo evaluate the efficacy and laryngeal function preservation of neoadjuvant treatment with chemotherapy and immune checkpoint inhibitor for locally advanced hypopharyngeal cancer (LAHPC).MethodsWe retrospectively collected LAHPC patients who were diagnosed between February 2022 and June 2023. The patients received a combination of chemotherapy and immune checkpoint inhibitors as the neoadjuvant therapy. The response to treatment, laryngeal function preservation rate, and short-term survival were assessed.ResultsA total of 20 patients were included. Of these patients, 17 (85.0%) had stage IVA-B disease. Ten (50%) and four (20%) patients achieved pathological complete response (PCR) and major pathological response (MPR) to the primary tumor, respectively. In addition, 6 patients had incomplete pathological response (IPR). In the neck, 19 patients had node-positive disease before treatment, and only 5 patients (26.4%) had PCR to regional lymph nodes. Pathologically positive lymph nodes were still observed in 14 (73.6%) patients. Significant downgrading on narrow-band imaging assessment in primary tumors was associated with a higher probability of PCR or MPR than those with IPR (92.9% vs. 33.3%, P=0.014). The overall rate of laryngeal preservation was 95.0%. No severe perioperative complications or perioperative death were found. All patients completed the recommended postoperative radiotherapy/chemoradiotherapy. The median follow-up period was 12.1 months. The 1-year progression-free survival and overall survival were 94.1% and 92.9%, respectively. During the follow-up period, all 19 patients who underwent laryngeal preservation surgery had their laryngeal function preserved.ConclusionThe addition of an immune checkpoint inhibitor to neoadjuvant chemotherapy effectively preserves laryngeal function without increasing complications related to surgery and postoperative radiotherapy in LAHPC.

Background CD74 is ectopically expressed in many tumors and can regulate tumor immunity. However, there are many gaps in the study of the prognostic value of CD74 expression and immune infiltration in hepatocellular carcinoma (HCC). Methods An online tumor database was searched to obtain data on gene/protein expression. Immune infiltration analysis was performed using the Tumor Immune Estimation Resource and Comprehensive Analysis on Multi-Omics of Immunotherapy in Pan-cancer databases. Single-cell data were obtained from the Tissue-specific Gene Expression and Regulation, Single-cell Transcriptomes of Tumor Immune Microenvironment and Tumor Immune Single-cell Hub 2 databases. Results CD74 was highly expressed in HCC patients. HCC patients with high CD74 expression who consumed alcohol or were negative for hepatitis virus had a better prognosis than patients with low CD74 expression. CD74 was mainly enriched in immune response regulation pathways. Both copy number variations in CD74 and CD74 expression patterns affected the infiltration levels of immune cells. Interestingly, CD74 regulated the differentiation of myeloid cells. CD74 in macrophages and dendritic cells (DCs) forms complex networks with malignant cells and hepatic progenitor cell (HPC)-like cells, respectively. High CD74 expression in HPC-like cells and malignant cells significantly decreased the fraction of C-type lectin domain family 9 A (CLEC9A)-cDC1(+) DCs and IL-1B(+) macrophages, respectively. Their crosstalk subsequently shaped the tumor microenvironment of HCC, possibly through the CD74-MIF axis. Importantly, patients with high CD74 expression presented higher immune scores and achieved good outcomes after receiving immunotherapy. Conclusion High CD74 expression is associated with the abundance of a variety of immune cell types, mediating interactions among tumor and immune cells and shaping the malignant behavior of HCC. In summary, CD74 may be a hallmark for determining the prognosis and immune cell infiltration levels of HCC patients.

Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.

The present study aimed to elucidate the role of MicroRNA-203b-3p (miRNA-203b-3p) in protecting the deterioration of laryngeal carcinoma through targeting ZNF324. Relative levels of miRNA-203b-3p and ZNF324 in laryngeal carcinoma tissues with different tumor node metastasis (TNM) staging and pathological grades were detected. Regulatory effects of miRNA-203b-3p on clonality, viability and 5-Ethynyl-2'- deoxyuridine (EdU)-positive ratio in M2E and TU212 cells were assessed. The binding relationship between miRNA-203b-3p and ZNF324 was evaluated by dual-luciferase reporter gene assay. The involvement of ZNF324 in cell phenotype changes of laryngeal carcinoma regulated by miRNA-203b-3p was explored by rescue experiments. MiRNA-203b-3p was downregulated in laryngeal carcinoma, especially in those with advanced TNM staging or pathological grade. Overexpression of miRNA-203b-3p reduced clonality, viability and EdU-positive ratio in M2E and TU212 cells. In addition, ZNF324 was upregulated in laryngeal carcinoma, which was negatively regulated by miRNA-203b-3p. ZNF324 was verified to be the target binding miRNA-203b-3p. Notably, overexpression of ZNF324 could partially reverse the inhibitory effects of miRNA-203b-3p on laryngeal carcinoma proliferation. MiRNA-203b-3p is downregulated in laryngeal carcinoma, which blocks laryngeal carcinoma cells to proliferate through targeting ZNF324 and thus alleviates cancer progression.

Objective To explore the clinical effect of video supported laryngoscopy surgery for the diagnosis and treatment of vocal nodules and vocal polyps in our hospital.Method A retrospective study was conducted on 125 patients with vocal nodules and vocal polyps who underwent surgical treatment in our hospital from January 2020 to June 2022.They were divided into vocal nodules,localized vocal polyps,and diffuse vocal polyps according to the morphology of electronic laryngoscopic tumors,and were treated with daytime center surgery under general anesthesia video laryngoscope.Result The effective rate of video laryngoscopy surgery was 98.4％,with significant therapeutic effects;There was a significant improvement in voice indicators before and after surgery,with a statistically significant difference(P＜0.05);There was a significant improvement in quality of life before and after surgery,as well as a significant improvement in scores of physiological/psychological function/mental health factors before and after surgery,with a statistically significant difference(P＜0.05);The total incidence of surgical adverse events was 4.8％.Conclusion Video assisted laryngoscopy is effective in the diagnosis and treatment of vocal nodules and vocal polyps,which can significantly improve the patient's hoarseness symptoms.Fine surgical procedures can help reduce complications,and postoperative vocal cord rest and oral anti reflux drugs can help reduce recurrence and improve the quality of the patient's voice.

Objective:To investigate the influential factors of the efficacy of tinnitus multivariate integrated sound therapy (T-MIST) in the treatment of subjective tinnitus.Methods:A total of 431 patients with subjective tinnitus who received treatment in The First Affiliated Hospital of Xiamen University from June 2019 to June 2020 were included in this study. A cross-sectional study method was used to conduct refined testing on tinnitus patients using the T-MIST matching platform. The severity of tinnitus patients was evaluated using the Tinnitus handicap inventory scale. SPSS software was used to analyze the factors affecting the effectiveness of the T-MIST for subjective tinnitus based on patients' basic characteristics.Results:Multivariate logistic regression analysis showed that compared with patients with short-term tinnitus, OR (95% CI) was 1.982 (1.033-3.804), P = 0.040, in patients with 3-12 months of disease duration, OR (95% CI) was 2.411 (1.322-4.396), P = 0.004 in patients with > 12 months of disease duration. With the increase in tinnitus handicap inventory score, the efficacy of T-MIST became better [ OR (95% CI) = 1.014 (1.004-1.024), P = 0.007]. The efficacy of T-MIST was better in the hearing compensation-effective patients [ OR (95% CI) = 0.133 (0.081-0.216), P < 0.001]. Conclusion:The course of the disease, tinnitus handicap inventory score, and effective hearing compensation are the influential factors of T-MIST. They can provide evidence for the treatment of subjective tinnitus.

目的 探讨宽频声导抗测试对耳硬化症及听骨链畸形在辅助诊断中的应用价值.方法 选取就诊于厦门大学附属第一医院耳科门诊的耳硬化症患者40耳,先天性中耳畸形患者10耳,另以正常健康志愿者(70耳)作为正常对照组,所有受试者术前均行宽频声导抗测试,比较各组患者峰压下的声能吸收率.结果 峰压下,正常对照组3％(2/70)在1kHz附近出现一切迹;峰压下,耳硬化症组5％(2/40)在1kHz附近出现切迹;峰压下,先天性听骨链畸形组70％(7/10)的患者在1kHz附近有一切迹.先天性听骨链畸形组患者在1kHz附近出现切迹的患者比例与耳硬化症组和正常对照组有显著性差异(P＜0.05).结论 大部分先天性听骨链畸形患者的宽频声导抗在1kHz附近会出现一切迹.宽频声导抗测试可作为术前辅助诊断耳硬化症和听骨链畸形的听力学检查方法之一.